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LPC, liver progenitor cell [16] . In particular, it has been proposed that Hh pathway activation is important in perpetuating an activated pro-fibrogenic phenotype [16, 17] . Studies have also reported the Hh pathway is involved in liver regeneration, and in the maintenance of intrahepatic stem/progenitor cells [16, 18] . A major limitation of these studies is that Hh signalling activation in vivo is only defined by GLI2 expression. As such, it has been impossible to define whether GLI regulation is SMOdependent or SMO-independent, in the proposed paradigm.
In this paper, for the first time, we have used Pc detection to carefully identify Such observations are critically important given the potential for Hh pathwayrelated therapeutics in liver disease treatment.
MATERIALS AND METHODS

Animal studies
Housing/experiments at the Centenary Institute performed in accordance with protocols imposed by the Animal Ethics Committee, University of Sydney weeks (wks) (n=3-10/group) prior to sacrifice. Non-treated control littermates were sacrificed at 20wks. Altered Hh pathway activation in vivo was studied using heterozygous Ptc1-lacZ reporter (Ptc1 +/-) mice [19] . Eight-week wild-type (wt) or Ptc1 +/-male mice were TAA-treated for 8wks (n=4-9/group).
Quantitative mRNA analysis
Outlined Supplementary Material, Suppl. Table 1 .
In situ hybridisation (ISH)
Murine specific RNA probe (sense/anti-sense) generation and ISH protocols were as previously described [20] . Primer sequences for probe generation outlined in Suppl. Table 2 . Mouse 6μm paraffin liver sections were used.
Specific hybridisation conditions/probe concentrations were 42 o C, 1.0μg/ml for Gli1; 45 o C, 2.5μg/ml for Shh. Sense RNA probes on an adjacent section served as a negative control, returning no specific signal.
Histology, immunohistochemistry and immunofluorescence
Outlined Supplementary Material. Isotype IgG controls were conducted in parallel (Supp. Fig. 1 ).
Cell culture/vector construction
Outlined Supplementary Material.
Viability assay
Cells ( DNA (12μg) using Lipofectamine2000, after selection with blasticidin.
Repeated minimum three times.
Luciferase assays
Cells ( there was a marked increase in Shh localised to the epithelial-mesenchymal interface, compared with minimal expression in control tissue (Fig. 1B) . Large Shh +ve cells exhibited characteristics of dysmorphic hepatocytes, often isolated and within the portal tracts (Supp. Fig. 5A ). In addition, small portal tract cells were Shh +ve , possibly implicating leukocytes, HSCs/myofibroblasts or LPCs as potential sources of Hh ligand.
Hedgehog ligand protein detection in vivo
To further characterise Hh-producing cells, immunohistochemistry was performed in liver tissue. Intense staining of IHH was localised to large damaged/dysmorphic hepatocytes in this chronic injury model (Fig. 1C) .
Confocal microscopy confirmed pan-Hh (SHH, IHH) protein expression within the fibrotic septa (Fig. 1D) . The staining localised to large cells that coexpressed epithelial cell marker pan-cytokeratin (pan-CK; Fig. 1E ), providing confirmation hepatocytes were the primary source of Hh ligands. In contrast to the ISH data, no pan-Hh ligand protein was detected in small portal tract cell populations (Fig. 1F , Supp. Fig. 5B ). However, Hh-producing hepatocytes were in close proximity to epithelial cell adhesion molecule (EpCAM) +ve LPCs, CD45 +ve leukocytes and vimentin +ve activated HSCs (Fig. 1F , Supp. Fig 5B) .
The same expression profile was observed in human alcoholic liver disease (ALD), with CK18 +ve hepatocytes at this interface the primary source of SHH (Suppl. Fig. 6 ).
Hedgehog pathway component expression
Intrahepatic Hedgehog pathway expression
The effectors of Hh pathway signalling are the GLI transcription factors, and since GLI proteins also regulate Gli1 transcription, this gene has been conventionally used as a readout of GLI activity. An incremental increase in whole liver Gli1 mRNA was observed from 4-20wks TAA ( Fig. 2A) . By TAA20wks this was accompanied by a significant increase in Ptc1 and Gli3, and a marked reduction in Hhip, a Hh pathway antagonist. Thus in TAA-induced cirrhosis, net upregulation of Hh signalling occurred with a combined 8.68-fold increase in Gli1 and 9-fold decrease in Hhip. Furthermore, increased GLI1-A and reduced GLI3-R (R, truncated/cleaved GLI3 repressor) proteins occurred by TAA-20wks (Fig. 2B ). Protein levels of GLI target genes (OSTEOPONTIN, CYCLIN D1, BCL-2) were also increased.
Gli1 mRNA localisation
The cellular source(s) of GLI1 in chronic liver injury were yet to be determined. Since a reliable commercial anti-GLI1 antibody was not available, ISH was performed on TAA-20wk liver tissue to detect Gli1 mRNA. Gli1 transcript was readily detectable in various cell populations at the epithelialmesenchymal interface (Fig. 2C) . Notably, Gli1 was detected in large dysmorphic hepatocytes, as well as small portal tract cell populations, in TAA20wk liver.
GLI2 expressing cell populations in TAA-treated liver in vivo
To determine which cell sub-population(s) could potentially respond to Hh signal, co-staining for cellular markers and GLI2 was performed. GLI2 was expressed by EpCAM +ve LPCs, as well as in a significant number of hepatocytes at the injury interface and lobule (Fig. 2D, Supp. Fig 7) .
Vimentin +ve HSCs/myofibroblasts and CD45 +ve leukocytes were also GLI2 +ve (Fig. 2E) . Interestingly, co-expression of GLI2 and pan-Hh (SHH, IHH) ligand was observed in a subset of large cells with hepatocyte morphology (Suppl. Fig. 7B ). This was consistent with our ISH data and suggests the large ligandproducing cells exhibiting an active GLI response are injured hepatocytes, located at the epithelial-mesenchymal interface (Fig. 1,2C , Suppl. Fig 5A) .
Identification of ciliated cells in vivo
In vertebrates, Hh ligands act on cells via SMO translocation to the Pc [8] . In TAA chronic liver injury, Pc were identified on numerous cells located within the portal tracts adjacent to the hepatic lobule (Fig. 3A) . These cells expressed EpCAM (Fig. 3A , Suppl. Fig 8A) and SMO was localised within the Pc axoneme, a commonly used readout of SMO signalling (Fig. 3A) . As identified earlier, EpCAM +ve cells also express GLI2 (Fig. 2D) (Fig. 1F) , was additionally always noted in close spatial association with fibrosis-driving α-smooth muscle actin (α-SMA) +ve HSCs (Suppl . Fig. 10A ); a phenomenon commonly seen in chronic liver injuries with a LPC response [21] . Further, most EpCAM +ve cells co-expressed biliary LPC marker CK19, and LPC/cancer stem cell marker CD133 (Suppl. Fig. 10B,C) .
A Pc/SMO-dependent GLI-mediated response is important for liver progenitor cell survival in vitro
To study the function of Hh signalling in Pc +ve liver cells in vitro, confocal microscopy was performed to determine which liver cell lines harbour Pc. proliferation/viability (respectively) by day 6, as compared to controls (Fig.   3C ). This confirmed the importance of Hh pathway signalling in cell growth/expansion of Pc +ve LPCs.
GLI-mediated transcriptional activity can be induced by growth factors in a SMO-independent manner in vitro
Following our in vivo observations, we hypothesised that liver injury-related growth factors might induce SMO-independent GLI-mediated transcriptional responses in liver cells. To address this, we examined Hh pathway activation within the Pc +ve BMOL1.2 LPC line, using a Gli-luciferase reporter assay
system. As predicted, BMOL1.2 cells treated with recombinant SHH (rSHH)
significantly upregulated luciferase activity compared to controls (Fig. 3D ).
Injury factors epidermal growth factor (EGF) and HGF also significantly increased GLI-dependent transcription, and to the same degree as rSHH (Fig.   3D ). Upregulation of a GLI-mediated response by EGF/HGF was completely abolished using specific inhibitors (Erlotinib, SGX523) whilst having no effect on the basal GLI-mediated response (Fig. 3E) . To assess the contribution of SMO-dependent and SMO-independent pathways in basal and induced GLImediated transcriptional responses (luciferase activity), BMOL1.2 cells were treated with non-targeting control or α-Smo siRNAs (Fig. 3F) . Intriguingly, α-Smo inhibited EGF-dependent induction of GLI, but did not prevent HGFinduced GLI signal. Also, although a significant decrease in basal luciferase activity was detected on SMO knockdown, it did not completely abolish luciferase activity.
Hh pathway manipulation in vivo: the functional role of SMOdependent Hh pathway activation in chronic liver injury
Ptc1 heterozygous mice (Ptc1 +/-) were used to test the contribution of SMOdependent Hh signalling in the TAA-induced liver injury model. Previous studies indicate Ptc1 +/-mice have an impaired ability to regulate SMOdependent Hh pathway signal, thus have increased baseline Hh pathway activation [19, 22] . Following TAA-8wks, Ptc1 +/-mice exhibited exacerbated liver injury compared to wt counterparts as determined by liver function testing and Picrosirius red staining for collagen I (Fig. 4A,D) . Upregulated Gli1 expression correlated with increased serum alanine aminotransferase (ALT) levels (Fig. 4B,C) . Expansion of EpCAM +ve and vimentin +ve populations was evident when compared with wt controls, indicating amplified regenerative and fibrotic responses (Fig. 4D) . Further, whole liver EpCAM and α-SMA protein levels were elevated in Ptc1 +/-mice (Fig. 4E) . Importantly, N-Hh protein increased with TAA-treatment, but levels were equivalent in wt and Ptc1 +/-mice, although Ptc +/-mice exhibited increased Hh pathway activity (Fig. 4B,E) .
As Hh signalling has been implicated in epithelial-to-mesenchymal transition (EMT) [23] , a selection of EMT genes were quantitated in wt vs. Ptc +/-TAAtreated mice (Suppl. Fig 12A,B) . The results show upregulation of EMTrelated genes (Vim, Bcl2, Snai1, Zeb2) in Ptc +/-mouse liver. However, the significant upregulation (p<0.01, Ptc +/-vs. wt TAA-treated) rather than downregulation of E-cadherin (Cdh1) does not support a specific EMT process. Additionally, it was of interest to note the significant correlation of Gli1 expression with EMT-related Hh target genes (Bcl2, Snai1, Zeb2) (Suppl. Fig 12C) . [8] [9] [10] , and the emerging relevance of SMOindependent GLI-mediated responses in injury and cancer [11] [12] [13] [14] [15] .
DISCUSSION
Hh ligand production has previously been reported by injured biliary [22] and hepatocyte epithelium [24] in experimental models/human injury. Looking specifically at hepatocellular damage, we reported similar results with hepatocytes at the epithelial-mesenchymal border producing copious Hh ligand in human ALD (SHH) and following TAA (SHH, IHH). ISH indicated small cell populations also produced Shh. The mRNA/protein discrepancy is unexplained at present as no technical issues were identified. We can only conclude that in the TAA model Hh protein is produced by injured hepatocytes. Other studies have shown Hh ligands to be released by hepatocytes following ER stress [25] and apoptosis [24] . Further, in non-TAA injury models Hh ligands were detected in HSCs/myofibroblasts [17] , endothelial cells [26] , leukocytes [27] and LPCs [18] following primary culture or in vitro.
Potential Hh-responsive cells have been identified in several models of liver injury and human liver diseases [16, 22, 23, 25, 28] . However, in these papers Hh-responsiveness in vivo has been defined by GLI2 staining only, without considering signalling via the Pc. Intrahepatic cell populations reported to be Hh-responsive include HSCs/myofibroblasts [17] , endothelial cells [26] , leukocytes [27] and LPCs [18] . Such a model proposes promiscuous Hh signalling to almost all cell populations within the liver during injury. We cannot refute the findings, as we noted Gli1 and GLI2 expression in similar populations. However Pc, the organelle required to transduce SMOdependent GLI transcriptional signals to downstream genes in vertebrate cells [8] [9] [10] , were not detected in hepatocytes, leukocytes or myofibroblasts in vivo despite an intensive search. Previous studies have established that hepatocytes and leukocytes do not express a Pc [29] . A study of Pc expression by HSCs in human cirrhosis established 2.4% of HSCs (5 of 210 cells) had an evident Pc [30] . The presence of SMO within the Pc, expressed
by EpCAM +ve cells in vivo confirmed that these cells are competent at receiving and responding to Hh ligand signals [8] .
Our findings confining Hh ligand cognate signalling to the EpCAM +ve /Pc +ve /SMO +ve /GLI +ve cell is compelling and is in keeping with Hh signal regulation that occurs in adult epithelial progenitor cell compartments in other diseases and niches [3] [4] [5] [6] . EpCAM +ve cells in the TAA model share LPC markers and further support the concept that Hh signalling is involved in maintaining the intrahepatic progenitor cell niche [18] .
In light of our observations, previous studies that report widespread GLI- recently documented in kidney fibrosis [12] and pancreatic carcinogenesis [15] . Thus, we confirmed with the current literature that in vivo manipulation of the Hh pathway alters the outcome of fibrosis [22, 23] . However, our interpretation using the TAA model and in vitro experimentation has led us to a paradigm distinct from the current literature (Fig. 4F) . The literature proposes a chronic liver repair model whereby Hh ligands produced by multiple cell types drive SMO-dependent pathway activation in many cell types to promote inflammatory, regenerative and fibrogenic responses [16] . In particular, the pro-fibrogenic model suggests SMO-dependent signaling in the HSC/myofibroblast, which perpetuates the fibrotic response [17] . This model has recently been expanded to include SMO as a master regulator of many cell types including the transformation of HSC/myofibroblasts into liver progenitor cells and hepatocytes [31] . However, this paper did not use Pc as a marker for Hh-responsive cells, and studied alternate liver injury models (bile duct ligation, methionine choline-deficient diet + ethionine (MCDE)) [31] . We activation/proliferation via cytokine/growth factor secretion [21] . We speculate GLI2 +ve /Pc -ve populations (hepatocytes, leukocytes, myofibroblasts) also located within the Hh niche, are not responding to Hh ligand through SMO given they do not have a Pc and cannot transduce the Hh signal in vivo [8] .
Instead, we suggest SMO-independent activation of GLI-mediated transcriptional response is occurring in these cell populations, driven by growth factors/cytokines and independent of Hh/PTCH1/Pc/SMO.
There is no question the Hh signalling pathway plays an important role in chronic liver disease pathogenesis. Given the great potential for use of small molecule inhibitors of SMO in the treatment of liver disease, it is critical to dissect the contributions of both SMO-dependent and SMO-independent GLImediated transcriptional responses in chronic liver disease. This has not been previously undertaken. The use of Pc as a marker to define Hh/PTCH1/SMO-GLI responses will undoubtedly bring more clarity to this evolving field. Confocal, 63x objective. 
